Eli Lilly

New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued to take it lost even more, about 25% of their original weight on average.'Even AI Rappers are Harassed by Police' | AI UnlockedTirzepatide was developed by Eli Lilly and was first approved in 2022 by the…

New research seems to show the potential of a CRISPR-based gene therapy meant to neuter certain forms of cardiovascular disease. In the world’s first human trial of the therapy, people given the highest doses experienced significant and long-lasting reductions in their low-density lipoprotein cholesterol (LDL-C). The treatment could be used to help people genetically predisposed to high LDL-C and its accompanying health risks.What Inspired Dominic Monaghan's Performance in Moriarty?The gene therapy is being developed by…

Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. Companies developing weight-loss drugs have raised or made deals valued at more than $1.4 billion since about a year ago. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all…

Versanis shareholders could receive as much as $1.925 billion in cash, in an upfront payment and additional payments if certain milestones are reached. Versanis shareholders could receive as much as $1.925 billion in cash, in an upfront payment and additional payments if certain milestones are reached. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is…

On Thursday, the Food and Drug Administration made a decision that’s likely to have a major impact on the landscape of Alzheimer’s disease research. The agency issued a full-throated traditional approval of the drug Leqembi, developed by the companies Eisai and Biogen. The drug is the first of its class to receive such approval and is intended to slow down the progression of the neurodegenerative disease.Will We See More of Uhura's Relationship with Spock? | io9 InterviewLeqembi is one of several antibody-based drugs that…

Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. Medicare enrollees can get the anti-amyloid treatment as a result of the agency’s full approval. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the…

If they prove to work safely, the therapies could help people lose so much weight that they supplant bariatric surgery. If they prove to work safely, the therapies could help people lose so much weight that they supplant bariatric surgery. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials…

Tablets could appeal to people who want to lose weight but despise needles, which injections like Ozempic require. Tablets could appeal to people who want to lose weight but despise needles, which injections like Ozempic require. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their…

Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. Developers of Alzheimer’s drugs have work cut out for them getting the treatments to patients. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the…

An effective pill for obesity treatment looks to be within reach. This week, Novo Nordisk announced the results of a Phase III clinical trial testing out an oral version of its in-demand drug semaglutide. The once-daily pill not only substantially outperformed a placebo but did as well as the injectable form of the drug—an already-approved medicine called Wegovy—with participants losing 15% of their body weight on average.Mental Health Apps Are a Privacy NightmareSemaglutide belongs to a class of drugs called GLP-1…